{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:34Z","timestamp":1793661034585,"version":"4.5.1"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bioorg.2026.109538","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T23:23:46Z","timestamp":1769469826000},"page":"109538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["ATR inhibitors: from targeting the DNA damage response to exploiting synthetic lethality\u2014A paradigm shift in Cancer therapy"],"prefix":"10.1016","volume":"171","author":[{"given":"Xin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wufu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoli","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109538_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4143\/crt.2024.688","article-title":"On behalf of the 50th anniversary Committee of the Korean Cancer Association, Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment","volume":"57","author":"Lee","year":"2025","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.bioorg.2026.109538_bb0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the human development index (2008\u20132030): A population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","article-title":"Endogenous DNA damage as a source of genomic instability in cancer","volume":"168","author":"Tubbs","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109538_bb0020","doi-asserted-by":"crossref","first-page":"a012559","DOI":"10.1101\/cshperspect.a012559","article-title":"DNA base damage by reactive oxygen species, oxidizing agents, and UV radiation","volume":"5","author":"Cadet","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"Macheret","year":"2015","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.bioorg.2026.109538_bb0035","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.3390\/cancers16203507","article-title":"Tolerance of oncogene-induced replication stress: A fuel for genomic instability","volume":"16","author":"Igarashi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109538_bb0040","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.celrep.2013.10.027","article-title":"ATR activates the S-M checkpoint during unperturbed growth to ensure sufficient replication prior to mitotic onset","volume":"5","author":"Eykelenboom","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2026.109538_bb0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109538_bb0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication stress and cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109538_bb0055","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109538_bb0060","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/molecules27082491","article-title":"Recent advances in synergistic antitumor effects exploited from the inhibition of ataxia telangiectasia and RAD3-related protein kinase (ATR)","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109538_bb0065","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1073\/pnas.93.7.2850","article-title":"cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein","volume":"93","author":"Cimprich","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.109538_bb0070","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","article-title":"A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors","volume":"62","author":"Ruiz","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109538_bb0080","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.4161\/cc.7.18.6689","article-title":"Activation of ATR and related PIKKs","volume":"7","author":"Mordes","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bioorg.2026.109538_bb0085","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: An essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1460412","article-title":"Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs","volume":"14","author":"Gong","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe0903044","article-title":"Synthetic lethality \u2014 a new direction in cancer-drug development","volume":"361","author":"Iglehart","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109538_bb0100","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109538_bb0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109538_bb0110","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","article-title":"Discovery of preclinical candidate AD1058 as a highly potent, selective, and brain-penetrant ATR inhibitor for the treatment of advanced malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45996-4","article-title":"The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment","volume":"15","author":"Hardaker","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109538_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as cancer therapy: A new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109538_bb0125","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109538_bb0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2017.158","article-title":"Cryo-EM structure of human ATR-ATRIP complex","volume":"28","author":"Rao","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0140","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109538_bb0145","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1091\/mbc.e04-11-1006","article-title":"ATRIP binding to replication protein a-single-stranded DNA promotes ATR\u2013ATRIP localization but is dispensable for Chk1 phosphorylation","volume":"16","author":"Ball","year":"2005","journal-title":"MBoC"},{"key":"10.1016\/j.bioorg.2026.109538_bb0150","doi-asserted-by":"crossref","first-page":"13436","DOI":"10.1074\/jbc.M115.708263","article-title":"The dimeric architecture of checkpoint kinases Mec1ATR and Tel1ATM reveal a common structural organization","volume":"291","author":"Sawicka","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sbi.2014.11.003","article-title":"PIKKs \u2014 the solenoid nest where partners and kinases meet","volume":"29","author":"Bareti\u0107","year":"2014","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0160","doi-asserted-by":"crossref","first-page":"37538","DOI":"10.1074\/jbc.274.53.37538","article-title":"Substrate specificities and identification of putative substrates of ATM kinase family members","volume":"274","author":"Kim","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0165","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2741\/4867","article-title":"Structural and strategic landscape of PIKK protein family and their inhibitors an overview","volume":"25","author":"Thiruvenkatam","year":"2020","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bioorg.2026.109538_bb0170","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gad.1666208","article-title":"TopBP1 activates ATR through ATRIP and a PIKK regulatory domain","volume":"22","author":"Mordes","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2026.109538_bb0175","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pbiomolbio.2020.10.009","article-title":"Structural basis of the (in)activity of the apical DNA damage response kinases ATM, ATR and DNA-PKcs","volume":"163","author":"Jansma","year":"2021","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/BJ20102162","article-title":"ATR signalling: more than meeting at the fork","volume":"436","author":"Nam","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2026.109538_bb0185","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1101\/gad.1685108","article-title":"How ATR turns on: TopBP1 goes on ATRIP with ATR: figure 1","volume":"22","author":"Burrows","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2026.109538_bb0190","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.3390\/cancers16203536","article-title":"A TRilogy of ATR'S non-canonical roles throughout the cell cycle and its relation to cancer","volume":"16","author":"Joo","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109538_bb0195","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.dnarep.2009.04.006","article-title":"Common mechanisms of PIKK regulation","volume":"8","author":"Lovejoy","year":"2009","journal-title":"DNA Repair"},{"key":"10.1016\/j.bioorg.2026.109538_bb0200","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.molcel.2007.11.015","article-title":"The DNA damage response: ten years after","volume":"28","author":"Harper","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109538_bb0205","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1083\/jcb.201905064","article-title":"Regulation of ETAA1-mediated ATR activation couples DNA replication fidelity and genome stability","volume":"218","author":"Achuthankutty","year":"2019","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0210","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109538_bb0215","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1128\/MCB.21.11.3725-3737.2001","article-title":"Rfc4 interacts with Rpa1 and is required for both DNA replication and DNA damage checkpoints in saccharomyces cerevisiae","volume":"21","author":"Kim","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0220","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.dnarep.2004.03.032","article-title":"Dial 9\u20131\u20131 for DNA damage: the Rad9\u2013Hus1\u2013Rad1 (9\u20131\u20131) clamp complex","volume":"3","author":"Parrilla-Castellar","year":"2004","journal-title":"DNA Repair"},{"key":"10.1016\/j.bioorg.2026.109538_bb0225","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1083\/jcb.200810185","article-title":"TopBP1 and DNA polymerase-\u03b1 directly recruit the 9-1-1 complex to stalled DNA replication forks","volume":"184","author":"Yan","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0230","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.dnarep.2009.03.011","article-title":"A tale of two tails: activation of DNA damage checkpoint kinase Mec1\/ATR by the 9-1-1 clamp and by Dpb11\/TopBP1","volume":"8","author":"Navadgi-Patil","year":"2009","journal-title":"DNA Repair"},{"key":"10.1016\/j.bioorg.2026.109538_bb0235","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.1547007","article-title":"The Rad9\u2013Hus1\u2013Rad1 (9\u20131\u20131) clamp activates checkpoint signaling via TopBP1","volume":"21","author":"Delacroix","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2026.109538_bb0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/nar\/gkq743","article-title":"Structure and function of the Rad9-binding region of the DNA-damage checkpoint adaptor TopBP1","volume":"39","author":"Rappas","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0245","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.cub.2016.10.030","article-title":"RPA-binding protein ETAA1 is an ATR activator involved in DNA replication stress response","volume":"26","author":"Lee","year":"2016","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0250","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ncb3415","article-title":"ETAA1 acts at stalled replication forks to maintain genome integrity","volume":"18","author":"Bass","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0255","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/ncb3422","article-title":"Activation of the ATR kinase by the RPA-binding protein ETAA1","volume":"18","author":"Haahr","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0260","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1","volume":"21","author":"Zhao","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0265","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0168-9525(96)81443-0","article-title":"Rad-dependent response of the chkl-encoded protein kinase at the DNA damage checkpoint","volume":"12","year":"1996","journal-title":"Trends Genet."},{"key":"10.1016\/j.bioorg.2026.109538_bb0270","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1097-2765(05)00092-4","article-title":"Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in xenopus egg extracts","volume":"6","author":"Kumagai","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109538_bb0275","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1128\/MCB.00492-06","article-title":"Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation","volume":"26","author":"Liu","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0280","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/emboj\/16.3.545","article-title":"Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation","volume":"16","author":"O'Connell","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.109538_bb0285","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tcb.2006.04.002","article-title":"Cdc25: mechanisms of checkpoint inhibition and recovery","volume":"16","author":"Karlsson-Rosenthal","year":"2006","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 axis in cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109538_bb0295","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1101\/gad.1067403","article-title":"Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance","volume":"17","author":"Brown","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2026.109538_bb0300","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI58928","article-title":"Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR","volume":"122","author":"Schoppy","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.109538_bb0305","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0310","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0315","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1101\/gad.452308","article-title":"ATR signaling can drive cells into senescence in the absence of DNA breaks","volume":"22","author":"Toledo","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2026.109538_bb0320","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1074\/jbc.M410873200","article-title":"Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage","volume":"280","author":"Helt","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0325","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by <span style=\"font-variant:small-caps;\">ATR<\/span> inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.109538_bb0330","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/ijms25020752","article-title":"Biology and development of DNA-targeted drugs, focusing on synthetic lethality, DNA repair, and epigenetic modifications for cancer: A review","volume":"25","author":"Watanabe","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2026.109538_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Current Research in Pharmacology and Drug Discovery"},{"key":"10.1016\/j.bioorg.2026.109538_bb0340","article-title":"Potential Promising of Synthetic Lethality in cancer Research and Treatment","author":"Karami Fath","year":"2024","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.bioorg.2026.109538_bb0345","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-deficient colorectal cancer cells are sensitive to the PARP inhibitor olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0350","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","article-title":"ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors","volume":"131","author":"Smith","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109538_bb0355","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/0008-5472.CAN-21-1707","article-title":"Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells","volume":"82","author":"Sun","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0360","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0365","doi-asserted-by":"crossref","first-page":"37139","DOI":"10.1074\/jbc.M307088200","article-title":"Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases","volume":"278","author":"Cortez","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0370","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1039\/b504418a","article-title":"Chemistry and biology of wortmannin","volume":"3","author":"Wipf","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0375","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1073\/pnas.1015251108","article-title":"Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators","volume":"108","author":"Huryn","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.109538_bb0380","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1158\/0008-5472.CAN-14-2650","article-title":"Identification of ATR\u2013Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity","volume":"74","author":"Kawasumi","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0385","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1021\/jm990628o","article-title":"Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles","volume":"43","author":"Arris","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0390","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109538_bb0395","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","article-title":"A pharmacological map of the PI3-K family defines a role for p110\u03b1 in insulin signaling","volume":"125","author":"Knight","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109538_bb0400","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/jm101520v","article-title":"Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo [h] [1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer","volume":"54","author":"Liu","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0405","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0410","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0415","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"Knegtel","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0420","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4- [(3 R)-3-methylmorpholin-4-yl]-6- [1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1 H -indole (AZ20): A potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0425","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1016\/j.bmcl.2012.04.036","article-title":"Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor","volume":"22","author":"Finlay","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109538_bb0430","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/jm501026z","article-title":"Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring","volume":"58","author":"Andrs","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0435","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0440","doi-asserted-by":"crossref","first-page":"21890","DOI":"10.1021\/acs.jmedchem.4c01595","article-title":"Discovery of ART0380, a potent and selective ATR kinase inhibitor undergoing phase 2 clinical studies for the treatment of advanced or metastatic solid cancers","volume":"67","author":"Carroll","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114945","article-title":"Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo [3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design","volume":"246","author":"Qi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0450","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1 H -indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno [3,2- d ]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0455","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0460","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bioorg.2026.109538_bb0465","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109538_bb0470","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1021\/acs.jmedchem.3c01917","article-title":"Discovery of the potent and selective ATR inhibitor Camonsertib (RP-3500)","volume":"67","author":"Black","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0475","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/ml500352s","article-title":"Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors","volume":"6","author":"Barsanti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109538_bb0480","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills Cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109538_bb0485","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The novel ATR inhibitor tuvusertib (M1774) induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs","volume":"23","author":"Jo","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109538_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-related (ATR) kinase: structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106535","article-title":"Design, synthesis, and biological evaluation of pyrido [3,2-d]pyrimidine derivatives as novel ATR inhibitors","volume":"136","author":"Duan","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0500","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/molecules28114521","article-title":"Design, synthesis, and biological evaluation of potent and selective inhibitors of Ataxia telangiectasia mutated and Rad3-related (ATR) kinase for the efficient treatment of Cancer","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109538_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115370","article-title":"Discovery of thieno [3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase","volume":"255","author":"Duan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128651","article-title":"Discovery of 6,7-dihydro-5H-pyrrolo [3,4-d] pyrimidine derivatives as a new class of ATR inhibitors","volume":"63","author":"Chen","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109538_bb0515","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bmcl.2017.01.045","article-title":"Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)","volume":"27","author":"Ramachandran","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109538_bb0520","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109538_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116159","article-title":"Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment","volume":"267","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116167","article-title":"Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase","volume":"267","author":"Alfayomy","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0535","article-title":"Discovery of selective and potent ATR degrader for exploration its kinase-independent functions in acute myeloid leukemia cells","volume":"63","author":"Wang","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioorg.2026.109538_bb0540","doi-asserted-by":"crossref","first-page":"21105","DOI":"10.1073\/pnas.1111919109","article-title":"Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress","volume":"108","author":"Bauer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.109538_bb0545","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201847026","article-title":"Checkpoint kinase 1 is essential for fetal and adult hematopoiesis","volume":"20","author":"Schuler","year":"2019","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bioorg.2026.109538_bb0550","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1084\/jem.20121061","article-title":"Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress","volume":"209","author":"Austin","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2026.109538_bb0555","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0560","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1200\/JCO.2024.42.16_suppl.8104","article-title":"A phase II, open-label, combination therapy of durvalumab and ceralasertib in relapsed and refractory small cell lung cancer (SUKSES-N4)","volume":"42","author":"Lee","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0565","series-title":"Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects","author":"Yap","year":"2025"},{"key":"10.1016\/j.bioorg.2026.109538_bb0570","series-title":"Baseline Predictors of Hematological Toxicity in Patients with Advanced Cancer Treated with ATR Inhibitors in Phase I\/II Clinical Trials","author":"Ngoi","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109538_bb0575","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: A novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109538_bb0580","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1093\/nar\/gkab628","article-title":"Loss of cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress","volume":"49","author":"Lloyd","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0585","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1158\/0008-5472.CAN-21-4339","article-title":"SMG8\/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance","volume":"82","author":"Llorca-Cardenosa","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0590","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1158\/0008-5472.CAN-21-4335","article-title":"Resistance to ATR inhibitors is mediated by loss of the nonsense-mediated decay factor UPF2","volume":"82","author":"O'Leary","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009176","article-title":"Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors","volume":"16","author":"Schleicher","year":"2020","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bioorg.2026.109538_bb0600","article-title":"Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0605","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.molonc.2014.09.012","article-title":"Development of pharmacodynamic biomarkers for ATR inhibitors","volume":"9","author":"Chen","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100802","article-title":"Chemo-phosphoproteomic profiling with ATR inhibitors berzosertib and gartisertib uncovers new biomarkers and DNA damage response regulators","volume":"23","author":"Jadav","year":"2024","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bioorg.2026.109538_bb0615","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1111\/febs.16217","article-title":"CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery","volume":"289","author":"Schleicher","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2026.109538_bb0620","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3390\/cells11152361","article-title":"The role of ATR inhibitors in ovarian Cancer: investigating predictive biomarkers of response","volume":"11","author":"Bradbury","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.109538_bb0625","doi-asserted-by":"crossref","first-page":"E638","DOI":"10.1016\/j.ijrobp.2019.06.1097","article-title":"MGMT-deficiency is a biomarker to guide treatment of solid tumors with temozolomide and ATR inhibitors","volume":"105","author":"Jackson","year":"2019","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"key":"10.1016\/j.bioorg.2026.109538_bb0630","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/path.6032","article-title":"Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition","volume":"259","author":"Sundararajan","year":"2023","journal-title":"J. Pathol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0635","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1158\/0008-5472.CAN-20-0057","article-title":"A genome-wide pooled shRNA screen identifies PPP2R2A as a predictive biomarker for the response to ATR and CHK1 inhibitors","volume":"80","author":"Qiu","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0640","doi-asserted-by":"crossref","DOI":"10.1002\/cjp2.350","article-title":"The Tokyo metropolitan innovative oncology research group (TMIG), copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma","volume":"10","author":"Ura","year":"2024","journal-title":"The Journal of Pathology CR"},{"key":"10.1016\/j.bioorg.2026.109538_bb0645","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","article-title":"Chemotherapy induced DNA damage response","volume":"14","author":"Woods","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bioorg.2026.109538_bb0650","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109538_bb0655","article-title":"Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy","volume":"12","author":"Xu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0660","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1078-0432.CCR-20-3358","article-title":"The challenge of combining chemo- and radiotherapy with checkpoint kinase inhibitors","volume":"27","author":"Van Bijsterveldt","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0665","article-title":"ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis","volume":"816\u2013818","author":"Hutcherson","year":"2019","journal-title":"Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis"},{"key":"10.1016\/j.bioorg.2026.109538_bb0670","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcac045","article-title":"ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe","volume":"5","author":"Heyza","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.bioorg.2026.109538_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101743","article-title":"The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin","volume":"36","author":"Su","year":"2023","journal-title":"Translational Oncology"},{"key":"10.1016\/j.bioorg.2026.109538_bb0680","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.2147\/OTT.S211560","article-title":"VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response","volume":"12","author":"Liang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bioorg.2026.109538_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167625","article-title":"ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer","volume":"1871","author":"Chun","year":"2025","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.bioorg.2026.109538_bb0690","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Matulonis, Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: A multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109538_bb0695","first-page":"1670","article-title":"The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma","volume":"17","author":"Wallez","year":"2018","journal-title":"Regression"},{"key":"10.1016\/j.bioorg.2026.109538_bb0700","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00635","article-title":"Randomized phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival and biomarker analyses","author":"Konstantinopoulos","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.bioorg.2026.109538_bb0705","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41416-020-0931-6","article-title":"Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models","volume":"123","author":"Tran Chau","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109538_bb0710","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1073\/pnas.91.9.3834","article-title":"PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro","volume":"91","author":"Gra\u00f1a","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.109538_bb0715","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1016\/j.annonc.2020.08.166","article-title":"13P synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status","volume":"31","author":"Giunta","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0720","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.3390\/cancers14071807","article-title":"Combinations of ATR, Chk1 and Wee1 inhibitors with olaparib are active in olaparib resistant Brca1 proficient and deficient murine ovarian cells","volume":"14","author":"Chiappa","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109538_bb0725","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109538_bb0730","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1126\/science.aan6490","article-title":"A mitosis-specific and R loop\u2013driven ATR pathway promotes faithful chromosome segregation","volume":"359","author":"Kabeche","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109538_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115095","article-title":"Targeted delivery of a colchicine analogue provides synergy with ATR inhibition in cancer cells","volume":"201","author":"Barnieh","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109538_bb0740","doi-asserted-by":"crossref","first-page":"15711","DOI":"10.1021\/acs.jmedchem.5c00718","article-title":"Enhancing solubility in VHL-based PROTACs: optimized USP7 degraders for improved developability","volume":"68","author":"Wittenburg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109538_bb0745","doi-asserted-by":"crossref","DOI":"10.1002\/fsn3.70011","article-title":"Navigating PROTACs in cancer therapy: advancements, challenges, and future horizons","volume":"13","author":"Ibrahim","year":"2025","journal-title":"Food Sci Nutr."},{"key":"10.1016\/j.bioorg.2026.109538_bb0750","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1038\/s41467-025-65590-6","article-title":"Highly efficient and long-acting split-and-mix proteolysis targeting chimera based on self-assembled polylactic acid","volume":"16","author":"Zhan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109538_bb0755","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsnano.4c11903","article-title":"Strategy and design of in situ activated protein hydrolysis targeted chimeras","volume":"19","author":"Lv","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioorg.2026.109538_bb0760","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/med.22101","article-title":"Unleashing the power of covalent drugs for protein degradation","volume":"45","author":"Fu","year":"2025","journal-title":"Med. Res. Rev."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:12:32Z","timestamp":1770973952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":152,"alternative-id":["S004520682600074X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109538","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATR inhibitors: from targeting the DNA damage response to exploiting synthetic lethality\u2014A paradigm shift in Cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109538"}}